Of particular note, “anti-insulin resistance” therapies, such as insulin, GLP-1 analogs, DPP-4 inhibitors, and APN, may improve insulin receptor signaling by up-regulating the activity of proteases such as IDE and KLK6. The gene discussed is GLP1R; the disease is Insulin resistance.